Overview

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Status:
Recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

Alberta Children's Hospital
Arkansas Children's Hospital Research Institute
M.D. Anderson Cancer Center
Milton S. Hershey Medical Center
Phoenix Children's Hospital
Stanford University
University of Texas